This application is a competing renewal of the UW/Fred Hutch CFAR, a Tier 3 CFAR in its 30th year and one of the original CFARs launched in 1988. The UW/Fred Hutch CFAR is a multidisciplinary and multi-institutional consortium including the University of Washington (UW), Fred Hutchinson Cancer Research Center (Fred Hutch), Center for Infectious Disease Research, Infectious Disease Research Institute, Seattle Children?s, and the University of Hawai?i (minority affiliate). Our CFAR has grown from 75 members in 1988 to 736 today, with members from 45 UW departments, all five Fred Hutch Divisions, and connections throughout Seattle, a global technology and innovation hub. NIH 2017 HIV funding to our five Seattle partners exceeds $169 million, an increase of 11% over the past five years and with representation from all NIH Institutes that co-sponsor the CFAR program; non-NIH HIV funding exceeds $365 million. The UW/Fred Hutch CFAR has catalyzed substantial growth in research infrastructure, domestic and international partnerships, research impact, and the development of emerging HIV researchers (with a return on investment on CFAR developmental awards of 1320%), demonstrating high added value and aided by significant institutional financial contributions. We have recently completed a 10-step strategic planning process for this application, seeking input from our members and advisory committees and intentionally evaluating and strengthening our structures and policies for improvement and prioritization. Key innovations for this proposal include our new Director, selected by a Succession Oversight Committee; doubling funding to our Developmental Core; merging two Cores and integrating two additional Cores into others, which will gain efficiencies and set new directions; building on our strong foundation in clinical and basic science; incorporating a robust monitoring and evaluation program; committing to the growth of new leaders across our Cores/SWGs; and defining a new Vision Statement with five Themes that underpin our work going forward: Global Impact, Multidisciplinary Science, Innovative and Cutting- Edge Expertise, Enabling Environment, Next Generation of HIV Research Leaders. Our overarching Strategic Aims are: (1) Catalyze multidisciplinary HIV research to achieve impact on the global epidemic, with work from bench to bedside to populations (and back); (2) Grow new researchers, research leaders, infrastructure, and resources to expand innovative multidisciplinary work to change the trajectory of the global HIV epidemic. Our Cores and SWGs will have multidisciplinary cross-connections, will provide novel science and services, and will include three Clinical Science Cores (Clinical Cohort and Comorbidity Research; Behavioral Science; Implementation Science), three Basic Science Cores (HIV-Associated Malignancies; Immunology; Retrovirology and Molecular Data Science), three cross-cutting Cores (Administrative; Developmental; Biometrics), and three Scientific Working Groups (Cure; Adolescent Health; eHealth). We are proud of our CFAR and its successes to date, and we eagerly are looking ahead to future CFAR-supported research, collaboration, and innovation.

Public Health Relevance

The UW/Fred Hutch Center for AIDS Research (CFAR) is a multi-institutional consortium based in Seattle which catalyzes new HIV research and develops new research leaders across the multidisciplinary spectrum of basic, clinical, epidemiologic, statistical, sociobehavioral, and implementation science expertise necessary to bend the curve of the global HIV epidemic. During 30 years of continuous funding, the UW/Fred Hutch CFAR has facilitated substantial growth in research infrastructure, domestic and international partnerships, research impact, and the development of emerging HIV researchers (with a return on investment on CFAR developmental awards of 1320%), demonstrating high added value and aided by significant institutional commitment. Through the work of our nine Cores and three Scientific Working Groups, we aim to expand multidisciplinary HIV research and grow new researchers, research leaders, infrastructure, and resources to achieve impact on the global epidemic, with work from bench to bedside to populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-32
Application #
9693154
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1997-03-01
Project End
2023-05-31
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
32
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Patel, Rena C; Bukusi, Elizabeth A; Baeten, Jared M (2018) Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother 19:1-12
Ross, Jennifer M; Ying, Roger; Celum, Connie L et al. (2018) Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics 23:34-41
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Smith, Robert A; Wu, Vincent H; Zavala, Christopher G et al. (2018) In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrob Agents Chemother 62:
Stekler, Joanne D; Violette, Lauren R; Niemann, Lisa et al. (2018) Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis 5:ofy197
Golob, Jonathan L; Stern, Joshua; Holte, Sarah et al. (2018) HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients. AIDS 32:2113-2118
Katz, David A; Golden, Matthew R; Hughes, James P et al. (2018) HIV Self-Testing Increases HIV Testing Frequency in High-Risk Men Who Have Sex With Men: A Randomized Controlled Trial. J Acquir Immune Defic Syndr 78:505-512

Showing the most recent 10 out of 1275 publications